Skip to main content
. 2019 May 17;8(5):470. doi: 10.3390/cells8050470

Table 2.

Summary of reports of drug screening with organoid methods.

Cancer type Organoid Type Library # Compounds Tested # Cases Tested Assay Conditions Reference
Colorectal CSC-derived Target-known inhibitors + chemo drugs 83 19 With 2% BME in culture medium on BME [76]
Breast CSC-derived EGFR/AKT/mTORC pathway inhibitors 6 28 With 2% BME in culture medium on BME [78]
Gastric CSC-derived Approved anti-cancer drugs 37 7 On 50% Matrigel [77]
Bladder CSC-derived Target-known inhibitors + chemo drugs 50 11 With 2% Matrigel in culture medium [102]
Liver CSC-derived NCI-Approved Oncology Drugs Set VII 129 5 In Matrigel [103]
Various CSC-derived Chemo drugs and targeted agents under clinical development 160 (single) + 120 (combination) 4 2D culture of organoids for screening [104]
Ovarian CSC-derived Target-known inhibitors + chemo drugs 22 10 With 2% Matrigel in culture medium on Matrigel [105]
Colorectal CSC-derived * Target-known inhibitors + chemo drugs 8 19 In Matrigel [106]
Endometrial CTOS Target-known inhibitors 79 5 (2 hit drugs evaluated in 12 CTOS lines) w/o matrix [100]
Colorectal CTOS Target-known inhibitors 71 1 w/o matrix [87]
Colorectal CTOS Target-known inhibitors + FDA-approved drugs 2427 2 (15 hit drugs evaluated in 30 CTOS lines) w/o matrix [42]

* Prepared by CTOS method. CSC, cancer stem cell; CTOS, cancer tissue-originated spheroid; BME, basement membrane extract.